Shingrix, the recombinant shingles vaccine used today, contains no live virus and cannot directly cause shingles or any other herpes outbreak. However, the strong immune response it triggers has been linked, in rare cases, to reactivation of the varicella-zoster virus already lying dormant in a person’s body. Whether it can also provoke a cold sore or genital herpes flare-up is a murkier question, and the answer depends on understanding that “herpes” is a family of viruses, not just one infection.
Why Shingrix Cannot Directly Give You Shingles
The older shingles vaccine, Zostavax, was a live but weakened form of varicella-zoster virus (VZV). In theory, a live vaccine could cause a mild version of the disease it was designed to prevent, and Zostavax carried warnings for people with weakened immune systems for exactly that reason. Shingrix replaced it and works completely differently. It contains a single protein fragment from VZV, called glycoprotein E, plus a potent adjuvant (AS01B) that ramps up the immune response. There is no intact virus in the syringe, so the vaccine itself is incapable of infecting you with VZV or establishing a new latent infection.
That distinction matters because shingles is not a new infection. It happens when VZV, the same virus that caused your childhood chickenpox, wakes up from decades of dormancy in nerve cells and travels along a nerve to the skin.1PubMed Central. A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation Since Shingrix contains no live VZV, any shingles episode after vaccination is the person’s own latent virus reactivating, not something the shot introduced.
Rare Cases of Shingles Shortly After Getting the Shot
Despite the vaccine being non-live, a small number of published case reports describe people developing a classic shingles rash within days to weeks of receiving Shingrix. In one report, a woman in her 60s with a healthy immune system developed a blistering, itchy rash along a single nerve pathway about a week after vaccination, along with fever and fatigue. She was diagnosed with herpes zoster reactivation and treated with a week-long course of an antiviral drug.2PubMed Central. Reactivation of Herpes Zoster After Recombinant Vaccine (Shingrix): A Case Report In another, an 85-year-old man developed a rash with scattered blisters on his neck and shoulder just one day after receiving Shingrix.3PubMed Central. Zoster-Like Dermatomal Eruption Following Recombinant Zoster Vaccine: A Case Report
These are individual case reports, and the timing alone does not prove the vaccine caused the reactivation. Post-marketing surveillance of Shingrix through the U.S. adverse event reporting system from 2017 to 2024 did flag herpes zoster among events reported more frequently than expected after vaccination. The authors of that analysis cautioned that a higher-than-expected reporting rate does not prove a causal connection but does warrant closer investigation.4PubMed Central. Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024 The overall picture is that if Shingrix-triggered VZV reactivation happens at all, it is uncommon enough that it appears mainly in case reports rather than in large clinical trials.
How the Adjuvant Could Stir Things Up
If a non-live vaccine cannot infect you, how might it wake up a dormant virus? The leading hypothesis centers on Shingrix’s adjuvant, AS01B. This ingredient is deliberately designed to provoke a strong immune response, which is why Shingrix is so effective. But “strong immune response” also means a burst of inflammatory signaling molecules, and that inflammatory surge could, in some people, disrupt the delicate standoff between their immune system and a latent virus hiding in nerve cells.
In mouse studies, injecting the recombinant zoster vaccine produced a sharp spike in inflammatory markers like IL-6 and G-CSF in muscle tissue within a day, and the spike was even larger after the second dose.5PubMed Central. Increased Production of Inflammatory Cytokines after Inoculation with Recombinant Zoster Vaccine in Mice Human studies of the same AS01B adjuvant (used in a hepatitis B vaccine) confirmed rapid, transient surges of multiple cytokines, peaking within about 12 to 24 hours and returning to baseline within a week.6Vaccine. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans Further lab work showed that AS01 activates immune cells and ramps up inflammatory pathways even in older adults.7PubMed Central. Adjuvant AS01 activates human monocytes for costimulation and systemic inflammation
The connection to viral reactivation is still theoretical. We know that various stressors, from fever to surgery to emotional upheaval, can trigger latent herpesviruses to reactivate. A powerful immune activation event like vaccination fits neatly into that category. But proving that any one vaccination caused a specific reactivation episode, rather than coinciding with one that would have happened anyway, is extremely difficult. Most researchers describe these post-vaccination reactivation cases as biologically plausible but unproven.
Cold Sores and Genital Herpes Are Different Viruses
When people hear “herpes breakout,” they usually think of cold sores (typically herpes simplex virus type 1, or HSV-1) or genital herpes (often HSV-2). These are entirely different viruses from the varicella-zoster virus that causes shingles, even though all three belong to the broader herpesvirus family. They infect different cell populations, establish latency in different ganglia, and reactivate through overlapping but distinct mechanisms.1PubMed Central. A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation
HSV reactivation can be triggered by a wide range of stimuli, including stress, illness, UV exposure, and immune system shifts.8Virology. Strength in diversity: Understanding the pathways to herpes simplex virus reactivation Since any vaccine that produces a significant inflammatory response could count as a temporary immune system disruption, it is plausible that Shingrix could trigger an HSV flare in someone who carries the virus. But there is no published research specifically examining Shingrix as a trigger for HSV outbreaks. The clinical literature on post-Shingrix herpes events focuses almost entirely on VZV, not HSV.
If you get a cold sore or genital herpes flare shortly after your shingles shot, it is worth mentioning to your doctor, but it does not mean the vaccine “gave” you herpes. You already had HSV, and the stress of the immune response may have provided the nudge for reactivation. That same nudge could come from a bad night’s sleep or a sunburn.
When a Rash After Vaccination Is Not What It Looks Like
One underappreciated problem in this area is misdiagnosis. A blistering rash that follows a nerve pathway looks, to the naked eye, like textbook shingles. But herpes simplex can produce the exact same pattern. A study published in the Journal of the American Academy of Dermatology reported three patients who were initially diagnosed with recurrent shingles, only to have viral cultures reveal HSV as the actual cause. The authors went further, arguing that most “recurrent zosteriform eruptions” are probably HSV and that a diagnosis of recurrent shingles should require laboratory confirmation.9PubMed. “Recurrent herpes zoster”: an unproved entity?
This means that when someone develops a rash after Shingrix and is told they have shingles, the diagnosis may not always be correct. Without a viral culture or PCR test, a clinician could easily confuse an HSV outbreak following the nerve pathway with VZV reactivation. If the case reports of “shingles after Shingrix” include some misdiagnosed HSV cases, the already small number of true VZV reactivation events would be even smaller. This is one reason doctors increasingly recommend laboratory confirmation for any unusual or recurrent zosteriform rash, particularly in the context of recent vaccination.
Eye Complications Deserve Special Attention
One area where post-vaccination VZV reactivation has received more focused study is herpes zoster ophthalmicus, or shingles affecting the eye. This is a serious condition that can damage the cornea and threaten vision. A published case report described a patient who experienced reactivation of herpes zoster keratitis a few weeks after receiving Shingrix, with at least one similar prior case documented in the literature.10PubMed Central. Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine
A larger study went beyond individual case reports. It examined the risk of herpes zoster ophthalmicus flare-ups after Shingrix vaccination and found that, after adjusting for multiple factors, people who received Shingrix had roughly 64 percent higher odds of an eye-related VZV exacerbation during the period shortly after vaccination compared to a control window.11JAMA Ophthalmology. Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination That is a statistically meaningful increase, though the absolute number of affected people was still small. For most people, the long-term protection Shingrix offers against shingles and its complications, including eye involvement, outweighs this short-term risk. But if you have a history of shingles in or around your eye, this is something to discuss with your ophthalmologist before getting vaccinated. Some eye specialists recommend prophylactic antiviral medication around the time of vaccination for patients with a history of ocular herpes zoster.
Other Vaccines and Herpesvirus Reactivation
Shingrix is not the only vaccine linked to herpesvirus reactivation. During the COVID-19 vaccination campaigns, reports emerged of both VZV and HSV outbreaks following vaccination. A systematic review and meta-analysis estimated VZV reactivation at roughly 14 per 1,000 COVID-19 vaccinations and HSV reactivation at about 16 per 1,000.12PubMed Central. Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis Those numbers are considerably higher than what has been reported after Shingrix, though direct comparison is tricky because the populations, surveillance methods, and reporting incentives differed enormously during the pandemic.
The broader point is that any strong immune stimulus has the potential to tip latent herpesviruses into reactivation. This is not unique to any one vaccine or adjuvant. Infections themselves do this too: a bad bout of the flu, COVID-19, or even severe stress can trigger shingles or a cold sore flare. The immune system is constantly keeping multiple latent viruses in check, and when something big temporarily reshuffles the deck, one of those viruses occasionally slips through.
The Surprising Link Between HSV and Shingles Risk
Here is a wrinkle most people would not expect: having been infected with herpes simplex virus may actually reduce your risk of getting shingles. A study comparing people who developed shingles with matched controls found that those who had never been exposed to HSV were about 55 percent more likely to develop shingles than those who carried HSV antibodies.13PubMed. Prior Herpes Simplex Virus Infection and the Risk of Herpes Zoster The explanation may involve cross-reactive immunity: because HSV and VZV are related alphaherpesviruses that share some structural features, immune responses built against one might provide partial surveillance against the other.
This finding is still being explored and should not be overinterpreted, but it illustrates how intertwined these viruses are from an immunological standpoint. It also adds a layer of complexity to the question of whether the shingles vaccine might provoke HSV activity. If HSV exposure strengthens the immune response against VZV, it is at least possible that immune stimulation targeting VZV could temporarily affect the equilibrium with HSV. None of this has been tested directly, and the clinical importance, if any, remains unknown.
Practical Guidance for People Considering Shingrix
For the overwhelming majority of eligible adults, the benefits of Shingrix far outweigh the theoretical risk of triggering a herpes outbreak of any kind. The vaccine is highly effective at preventing shingles and its most feared complication, postherpetic neuralgia, the chronic nerve pain that can linger for months or years after a shingles episode. A few practical considerations can help if you are concerned:
- History of shingles: Having had shingles before is actually a reason to get vaccinated, not a reason to skip it. The virus can reactivate more than once, and Shingrix reduces that risk substantially.
- History of ocular shingles: If you have had shingles involving the eye, talk to your eye doctor before your Shingrix appointment. Prophylactic antiviral medication around the time of vaccination may be appropriate.
- Frequent cold sores or genital herpes flares: There is no specific guidance for people with active HSV, because the risk of Shingrix triggering an HSV outbreak has not been formally studied. If you are on daily suppressive antiviral therapy for HSV, there is no reason to stop it for vaccination.
- Immunocompromised individuals: Because Shingrix is non-live, it is generally considered safe for people with weakened immune systems, unlike the old live vaccine. However, these individuals may also be at higher baseline risk for any herpesvirus reactivation, so coordination with a specialist makes sense.
Side effects from Shingrix are common and can be intense. Pain at the injection site, fatigue, muscle aches, and headache affect a large proportion of recipients, and the second dose tends to hit harder. These reactions reflect the robust immune activation the adjuvant is designed to produce. They are uncomfortable but temporary, usually resolving within two to three days. Developing a blistering rash along a nerve pathway is a very different event from these expected side effects and should prompt a visit to your doctor, ideally with laboratory testing to determine whether the cause is VZV, HSV, or something else entirely.
Why Laboratory Testing Matters More Than You Would Think
One recurring theme across the medical literature on post-vaccine rashes is that clinical appearance alone is unreliable for distinguishing between VZV and HSV. A rash that follows a dermatome (a strip of skin supplied by a single nerve) and features grouped blisters can be caused by either virus. Without a PCR swab or viral culture, the two are functionally indistinguishable at the bedside.9PubMed. “Recurrent herpes zoster”: an unproved entity? This is relevant far beyond the vaccine context. A person who believes they keep getting shingles might actually be experiencing recurrent HSV, which has different treatment considerations and a different long-term outlook.
If you develop a suspicious rash after vaccination, ask your doctor to swab an open blister for viral PCR testing. The result will tell you exactly which virus is involved, guide the right antiviral treatment, and help your medical team decide whether any special precautions are needed for future vaccine doses. It is a simple test that eliminates guesswork and gives you much better information than a visual diagnosis alone.